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 ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not 
Bevacizumab is an effective treatment in inhibiting the growth of recurrent pterygium. 
Study Design: Review of three published, English language randomized controlled trials 
published in 2010, 2012, and 2013.  
Data sources: Three randomized controlled trials measuring the efficacy of Bevacizumab to 
inhibit the growth of recurrent pterygium were found using PubMed and OVID databases.  
Outcome(s) Measured: The severity and progression of pterygium recurrence as well as corneal 
neovascularization were the main outcomes measured. Conjunctival injection, thickness, and size 
of the fibrovascular tissue were examined in subjects using ophthalmic evaluation including 
visual acuity testing, applanation tonometry, lit-lamp biomicroscopic examination, slit-lamp 
photography, indirect ophthalmoscopy, and corneal photographs.  
Results: In the study by Fallah, all groups failed, meaning fibrovascular tissue stretched onto the 
cornea. However, the mean duration for invasion of cornea in study group patients was 
significantly longer than for control group patients. The study by Lekhanont showed that 
Bevacizumab significantly transiently decreased the conjunctival injection. However, true 
recurrence was found in 62 of 80 patients with no statistically significant difference among the 
groups. In the study by Ozgurhan, pterygium recurrence was not noted in any patients in the 
study group, but was noted in 2 of 22 eyes in the control group. Moreover, corneal 
neovascularization was noted in 5 of 22 eyes in the control group but in none of the patients of 
the study group.  
Conclusion: The results of two of the randomized trials showed that Bevacizumab delays the 
recurrence of impending recurrent pterygium, but does not completely inhibit it. One of the 
randomized trials showed that Bevacizumab was an effective therapy for reducing recurrent 
pterygium and corneal neovascularization, but results were not statistically significant. Overall 
consistency was not provided and the data was inconclusive. All trials were limited due to small 
sample size and lack of follow-up studies.   
Key Words: Recurrent pterygium; Bevacizumab; Avastin; VEGF 
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INTRODUCTION 
Pterygium is a proliferative conjunctival lesion that consists of fibrovascular tissue and 
extends onto the cornea. It can cause significant astigmatism and severe visual impairment.6 
Recurrent pterygium, which is not uncommon after pterygium excision surgery, can be more 
symptomatic and problematic to eliminate than primary pterygium.6 This systematic review 
evaluates three randomized controlled trials comparing the efficacy of Bevacizumab for 
inhibiting the growth of recurrent pterygium.  
In 2013, the prevalence of pterygium worldwide was estimated to be 10.2%. 9 Prevalence 
varies depending on the population studied, and it is more common in tropical regions.6 Within 
the U.S., prevalence rates vary from less than 2% to between 5% and 15% depending on 
locations.12 Increased age and sun exposure are risk factor for the development of this lesion.6 
 Pterygium is usually managed by ophthalmologists, but it may be initially identified and 
treated by general practitioners. There are relatively few Physician Assistants (PAs) working in 
ophthalmology today.7 However, the U.S. is currently facing a projected shortage of 
ophthalmologists, and one solution may be for ophthalmologists to work with more PAs.7 The 
exact healthcare cost of pterygium has not been specified; however, the cost of vision-related 
diseases in 2013 was estimated to be $139 billion.1 The average cost of pterygium excision 
surgery with grafting is estimated to be $3,000.3 An exact number of healthcare visits for 
pterygium was not specified; however, the number of ambulatory care visits for disorders of the 
eye and adnexa, excluding glaucoma, cataract, disorders or refraction and accommodation, 
conjunctivitis, and disorders of eyelids, was 11,899 in 2009.2  
 The natural history, etiology, and pathogenesis of pterygium are poorly understood. It is 
unclear how pterygium converts from active, which refers to growing over months to years, to 
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inactive, which refers to static without increase in size.6 It is believed that angiogenesis plays a 
key role in the formation of fibrovascular tissue in recurrent pterygium.10 The most common 
symptoms of pterygium range from none to redness, irritation, pruritus, discomfort, swelling, and 
blurring of vision.6 Pterygium may induce astigmatism, and it can cause adverse effects on vision 
if proliferation reaches the visual axis.6,12 Patients with a small pterygium are treated 
symptomatically with ocular lubricants; larger lesions that impair visual acuity or eye movement 
are treated by surgical excision of the lesion.6 Recurrence rates after pterygium surgical excisions 
are high, and the recurrent lesions may be more inflamed or grow larger than the initial lesions.6 
 Intraoperative and postoperative adjunctive treatment modalities to prevent recurrence of 
pterygium currently used include mitomycin C, 5-fluorouracil, corticosteroids, and beta 
irradiation.4 Currently used adjunctive measures decrease recurrence rates substantially, but 
reported rates vary widely, and none have been proven to be completely safe and effective.4 
Pterygium recurrences and repeated excisions can lead to disruption of the ocular surface and 
subsequent complications.6 As mentioned earlier, angiogenesis has been noted to be a factor in 
pterygium formation and progression.10 Vascular endothelial growth factor (VEGF) is one of the 
most important factors in angiogenesis; therefore, blocking this factor may inhibit 
angiogenesis.10 Bevacizumab is an anti-VEGF agent and is thought to have potential value in the 
inhibition of growth of recurrent pterygium by inhibiting angiogenesis. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not Bevacizumab 
is an effective treatment in inhibiting the growth of recurrent pterygium.  
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METHODS 
 This review consists of three prospective, randomized controlled trials that met certain 
criteria. The population studied included subjects over 18 years old who developed recurrent 
pterygium after pterygium surgical excision. Two of the studies reviewed compared 
Bevacizumab to topical corticosteroids (Lekhanont8, Fallah4) and one of the studies compared 
Bevacizumab to artificial tears (Ozgurhan10). More specifically, the interventions compared in 
the study by Ozgurhan were the use of topical Bevacizumab (5mg/mL) QID x 2mo vs. artificial 
tears QID x 2mo; this was a double blinded study, and the administration of both interventions 
took place one month after subjects had recurrent pterygium excision surgery. Lekhanont 
compared using a single intralesional subconjunctival injection of Bevacizumab at 3 different 
doses: 1.25 mg/0.05mL; 2.5mg/0.1mL; 3.75mg/0.15mL vs. topical 0.1% fluorometholone eye 
drops QID x 4wks. Finally, Fallah compared the use of 1 eye drop of Bevacizumab 5mg/mL BID 
with betamethasone QID for 1 week vs. betamethasone QID for 1 week only.  
 The outcomes measured in all three studies were all based on patient oriented evidence 
that matters (POEMS). The progression and severity of the pterygium in subjects’ eyes after 
having had pterygium excision surgery was the main outcome measured. The severity of 
impending recurrent pterygia was measured by looking at conjunctival injection thickness, size 
and thickness of fibrovascular tissue, and scleral vessels as well as corneal neovascularization. 
Side effects and complications after applying treatment were also measured to assess the safety 
and tolerability of Bevacizumab for the treatment of pterygium.  
 Key words used to research for this topic included recurrent pterygium, Bevacizumab, 
Avastin, and VEGF. All three articles were published in English, and published in peer-reviewed 
journals. The author researched the articles using PubMed, OVID, and COCHRANE databases. 
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Articles were selected based on their relevance to the author’s clinical question and whether they 
included POEMS. Inclusion criteria during the author’s research included randomized controlled 
trial prospective studies published after 1999. The three studies selected were published between 
2010 and 2013. Exclusion criteria included studies that included subjects under 18 years old with 
a past medical history of any ocular surface disease or any other ocular surgery besides the ones 
being currently studied. The statistics reported and used were numbers needed to treat (NNT), 
relative benefit increase (RBI), absolute benefit increase (ABI), relative risk increase (RRI), 
absolute risk increase (ARI), numbers needed to harm (NNH), and p-values.  
Table 1: Demographics and Characteristics of Included Studies 
Study Type  # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Ozgurhan, 
2013  
RCT 44 20-
77 
Pts. 18 years 
and older who 
had recurrent 
pterygium as 
well as the 
ability to 
provide 
written 
informed 
consent and 
to comply 
with 
assessments 
for the full 
duration of 
the study.  
History of a 
major 
systemic 
condition or 
any ocular 
surface 
disease 
besides 
pterygium, 
uveitis, 
retinal 
vascular 
diseases, and 
previous 
conjunctival 
or scleral 
surgery 
0 Use of topical 
bevacizumab 
(5mg/mL) QID 
x 2mo VS. 
artificial tear 
QID x 2mo 
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Lekhanont, 
2012  
RCT 80 31-
67 
Impending 
recurrent 
pterygium 
developed 
within 6 
months after 
pterygium 
surgery  
Failure of 
conventional 
topical anti-
inflammatory 
therapy for 
impending 
recurrent 
pterygium. 
18y or older 
and good 
compliance 
with study 
regimen.   
Hx of any 
adjunctive 
treatment, 
such as 
mitomycin C. 
Other ocular 
surface 
pathologies 
or coexisting 
ocular 
diseases.  
Hx of allergy 
to the 
medications 
used in the 
study.  
Other ocular 
surgeries 
within the 
previous 
6mo.  
0 Single 
intralesional 
subconjunctival 
injection of 
Bevacizumab at 
3 different 
doses: 1.25 
mg/0.05mL; 
2.5mg/0.1mL; 
3.75mg/0.15mL  
VS Topical 
0.1% 
fluorometholone 
eye drops QID x 
4wks 
Fallah, 
2010  
RCT 54 >18 Pts. Who had 
undergone 
pterygium 
excision and 
developed 
impending 
recurrent 
pterygium.  
Anterior 
surface 
complications 
or any other 
ocular 
surgery. Pts. 
With platelet 
disorders or 
HTN.  
0 1 Eye drop of 
bevacizumab 
5mg/mL BID 
with 
betamethasone 
QID for 1 week 
VS 
Betamethasone 
QID for 1 week 
only 
 
OUTCOMES MEASURED 
 The main outcome measured was an increase in the size of fibrovascular tissue or true 
pterygium recurrence, which was defined by conjunctival fibrovascular tissue extending onto the 
cornea. The severity of impending recurrent pterygium was assessed depending on the scoring of 
conjunctival injection, thickness, and size of the fibrovascular tissue. Neovascularization was 
assessed by the presence of new vessels extending onto the cornea without conjunctival fibrous 
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tissue. Subjects underwent ophthalmic evaluation including visual acuity testing, applanation 
tonometry, lit-lamp biomicroscopic examination, slit-lamp photography, indirect 
ophthalmoscopy, and corneal photographs. Visual analog scales were used to evaluate symptoms 
and signs such as ocular irritation. These were recorded in a double-blinded fashion. Adverse 
reactions and complications were compared between study groups.  
RESULTS 
 In the study by Ozgurhan, 44 eyes of 44 subjects at the Beyoglu Eye Research and 
Training Hospital, located in Istanbul, Turkey, were studied for a total of 6 months. Subjects 
were seen before having recurrent pterygium excision surgery, and were thereafter seen at 1 day, 
1 week, 1 month, 2 months, 3 months, and 6 months after surgery.  Treatments were applied at 
the 1month follow up visit. No instances of pterygium recurrence were noted in the study group, 
whereas recurrence in 1 eye was noted 1month after treatment in the 2 month follow up visit, and 
one additional recurrence was noted 2 months after treatment in the 3 month follow up visit. A 
total recurrence in 2 eyes of the control group was present at the 6 month follow up visit. 
However, this was not considered to be statistically significant (p=0.244). The patients in the 
control group who failed received topical Bevacizumab, which resulted in the inhibition of the 
advancement of their pterygium.  
 Corneal neovascularization was not seen in the patients in the study group. However, it 
was seen in 4 eyes of the control group in the 2 month follow up visit (p=0.053), and in 1 eye in 
the 3month follow up visit (p=0.024). A total of 5 eyes in the control group developed corneal 
neovascularization by the 6 month follow up visit (p=0.024); a statistical significant was noted 
between treatment and control groups based on the p value. Topical Bevacizumab was also given 
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to these patients in the control group who failed, which prevented corneal neovascularization 
from advancing and even thinned some of the vessels.  
 None of the subjects withdrew from the experiment, and all of the subjects’ results were 
provided. SPSS version 16 was used for statistical analysis. The calculations for efficacy and 
safety can be seen in Table 2. The NNT was calculated to be -11 and is interpreted as followed: 
for every 11 patients treated with Bevacizumab, one fewer would experience inhibition in 
pterygium recurrence compared to control. There were no systemic or ocular side effects 
experienced by subjects who were administered the topical Bevacizumab. To measure safety of 
these medications, NNH was calculated and the result was -4. This would be interpreted as 
followed: For every 4 patients treated with Bevacizumab, one less would experience adverse 
effects.  
Table 2: Bevacizumab and Pterygium Ozgurhan Study10 
CER EER RBI ABI NNT p-value 
0.09 0 -1 -0.09 -11 0.244 
 
CER EER RRI ARI NNH p-value 
22.7% 0% -1 -22.7% -4 0.024 
 
 In the study by Lekhanont, 80 eyes of 80 subjects were recruited in the eye clinic at the 
Ramathibodi Hospital, Bangkok, Thailand. Subjects chosen had developed recurrent pterygium 
in a mean time of 2.5 months after having pterygium excision surgery. Each treatment was given 
to subjects and then followed from 3-18 months. 3 days after application of the respective 
treatments, conjunctival injection significantly decreased in all treatment groups. 1 week after 
treatment, only the groups who received 2.5mg and 3.75mg of Bevacizumab continued to show a 
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significant reduction in conjunctival vascularization. Decrease in conjunctival injection was 
observed until 2 weeks for the group who received 2.5mg of Bevacizumab, and until 3 weeks for 
the group that received the highest dose of Bevacizumab, 3.75mg. At later points, conjunctival 
hyperemia increased back to its pre-injection states at later time points. Patients in the control 
group who received the topical corticosteroid only showed no regression of vessels at any point 
during the duration of the study.8  
 No significant difference in the mean severity score improvement among the treatment 
groups was observed, and no change in thickness and size of the pterygia was noted at any 
Bevacizumab doses during the study. At the 3 month follow up, true pterygium recurrence was 
found in 62 subjects. No statistically significant difference in the recurrence rate was noted 
among the groups (p=0.82). Recurrent pterygia showed to have a greater fibrovascular 
proliferative response than the original pterygia, and rebound hyperemia and inflammation were 
seen in the majority of the subjects. Side effects from the Bevacizumab treatment included pain 
after injection and subconjunctival hemorrhage; these were noted in 3 subjects.  
 A single subconjunctival Bevacizumab injection was effective in temporarily reducing 
conjunctival vascularization in impending recurrent pterygium; it had no effect on the size and 
thickness of the lesions. It was shown that Bevacizumab is unlikely to reduce the recurrence rate 
for impending recurrent pterygium. Statistical analysis was performed using SPSS version 14; 
Paired t test and Wilcoxon signed rank test were also used to determine the significance of 
changes after treatment. Results for calculations of efficacy and safety can be seen in Table 3. 
The NNT for this study is 4 and is interpreted as followed: For every 4 patients treated with 
Bevacizumab, one additional patient will have inhibition of the pterygium.   
Table 3: Bevacizumab and Pterygium: Lekhanont Study8 
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CER EER RBI ABI NNT p-value 
80% 75% -0.0625 0.25 4 0.82 
 
 In the study by Fallah, 54 eyes of 54 patients who developed recurrent pterygium after 
having pterygium excision surgery were randomly divided into treatment and control groups and 
followed for 3-6 months. Subjects were recruited from the Tehran University Eye Research 
Center. The mean ages of the treatment group and control group were 49.96 and 51.61 
respectively; the age ranges of the subjects were not provided. It was noted whether the patients 
started the treatment 30 days prior to or 30 days following pterygium surgery. Means of 
progression of fibrovascular tissue were measured in the first week, first month, and three 
months of follow up after treatment was given to each of the groups.  
 The data in the study was continuous, and was unable to be converted into dichotomous 
data. The duration of progression of fibrovascular tissue to invasion of the cornea was calculated, 
and results were analyzed using the software SPSS version 13. All patients in both groups failed, 
meaning that fibrovascular tissue spread onto the cornea. However, Table 4 shows there was a 
statistical significance difference (p<0.01) in time in which this happened between the groups. 
The duration for invasion of cornea was longer in the treatment group, and the mean progression 
of fibrovascular tissue was less than in the control group. Table 5 shows there was also a 
statistical significance in the time needed for invasion of the cornea with fibrovascular tissue in 
treatment patients compared to control patients when the drugs were started less than 30 days 
and more than 30 days following surgery.  
Table 4: Progression after starting treatment4 
 Treatment group Control group P value 
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One week 1.916± 0.375 2.740± 0.517 <0.01 
One month 15.998± 1.22 27.230± 4.700 <0.01 
Three months 37.671± 13.1 59.247± 9 .472 <0.01 
Time for corneal invasion (days) 90.538±51.569 44.892±18.905 <0.001 
Table 5: Duration for corneal invasion following initiation of treatment after surgery4 
 <30 days >30 days P value 
Treatment group 119.6± 52.6 61.4± 30.5 0.002 
Control group 54.0± 20.8 34.3± 8.4 0.004 
 
DISCUSSION 
 This systematic review investigated three RCTs for the effectiveness of Bevacizumab 
in inhibiting the growth of recurrent pterygium. Each article selected subjects who had recurrent 
pterygium after having previous pterygium excision surgery. The blinding during the 3 RCTs 
was without error, and none of the subjects withdrew from the experiments. 
 Bevacizumab is a monoclonal antibody considered to be an anti-angiogenesis agent 
due to its ability to inhibit VEGF.5 It is currently approved by the FDA to be used as a first line 
drug against metastatic colorectal cancer.5 Some of the most common systemic side effects 
include epistaxis, thromboembolic events, hypertension, rhinitis, and proteinuria.5 Intravitreal 
Bevacizumab has been used as an off label treatment of age related macular degeneration with 
good results.11 Although no systemic side effects and no obvious safety outliers have been noted 
with intravitreal use, more studies need to be done to determine the safety of topical 
Bevacizumab.11 
All three studies used different dosages of Bevacizumab, and in one of the studies 
Bevacizumab was given along with a topical corticosteroid. There were several limitations 
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expressed by each study. The study by Lekhanont noted that the dose of Bevacizumab given 
might have been insufficient to have the desired effect.8 The treatment was given 2.5 months 
after the excision surgery, and it was noted that the treatment might have been more effective if 
given sooner after surgery, before regrowth of fibrovascular tissue already occurred.8 Small 
sample size and short follow up time were further limitations noted.8 The study by Fallah noted 
that the quantity and limited amount of time Bevacizumab was administered to subjects was the 
main possibility for the treatment’s failure.4 Finally, the study by Ozgurhan noted that the small 
sample size and short follow up time were the main limitations in the study.10  
CONCLUSIONS 
 Two of the studies showed that Bevacizumab is not an effective treatment in inhibiting 
the growth of recurrent pterygium; however, they showed that it delayed the recurrence of the 
disorder. The other study showed inhibition of growth in pterygium, however, the results were 
not statistically significant. Therefore, the evidence analyzed in this systematic review is 
inconclusive. Future study is warranted to evaluate topical Bevacizumab as a treatment to inhibit 
the growth of recurrent pterygium before routine use can be recommended and approved by the 
FDA.  
 Future studies evaluating the effectiveness of Bevacizumab should include larger study 
groups within the United States. There should also be a more consistent amount of time between 
the pterygium excision surgery and the start of treatment in the study groups. The results of the 
studies analyzed in this systematic review demonstrated significant potential of Bevacizumab to 
inhibit recurrent pterygium. Current ongoing studies are being done in England and in the U.S. to 
determine the effectiveness of Bevacizumab in the treatment of choroidal neovascularization 
which will help shed light on the safety of the drug when applied topically.11 
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